Leukemia and Lymphoma

Aims & Scope

Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies.

The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology.

Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor.

Leukemia & Lymphoma is also dedicated to education in the form of reviews, commentaries, conference summaries and emerging drug profiles.

All submissions are subject to peer review and disclosure requirements, as stipulated by the International Committee of Medical Journal Editors (ICMJE).

Rapid turnaround time for reviews as well as fast online publication assure timely access to accepted publications.

The journal provides a premier reference source for physicians and scientists interested in clinical, translational, and laboratory research, as well as clinical diagnosis and treatment of patients with malignant hematological disorders.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.2
2024	2.20

SJR (SCImago Journal Rank)

Year	Value
2024	0.778

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	105

Journal Rank

Year	Value
2024	7048

Journal Citation Indicator

Year	Value
2024	1941

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Report on the First International Workshop on interim-PET scan in lymphoma

  Citation: 627

  Authors: Michel, Andrea, Michel, Andrea, Corinne

• CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy

  Citation: 274

  Authors: R. H., E.

• Management of adverse events associated with idelalisib treatment: expert panel opinion

  Citation: 262

  Authors: Steven E., Jacqueline C., Jennifer R., Sven, Richard R., Michael J., Daniel, Susan M., John M., Martin H., Jeff P., Nai-Shun, Andrew D.

• Preclinical<i>versus</i>clinical drug combination studies

  Citation: 261

  Authors: Ting-Chao

• Hyperleukocytic Leukemias and Leukostasis: A Review of Pathophysiology, Clinical Presentation and Management

  Citation: 257

  Authors: Pierluigi, Larry D., Elizabeth W., Sumeet, Constance M., Attilio, Leo J.

• Triptolide, A Novel Immunosuppressive and Anti-Inflammatory Agent Purified from a Chinese Herb Tripterygium Wilfordii Hook F

  Citation: 247

  Authors: Benny J.

• Indirubin and Meisoindigo in the Treatment of Chronic Myelogenous Leukemia in China

  Citation: 244

  Authors: Zhijian, Yushu, Bingcheng, Lingsheng

• Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

  Citation: 234

  Authors: Yuan Xiao, K. Martin, A. Keith

• Pathways and mechanisms of venetoclax resistance

  Citation: 226

  Authors: Prithviraj, Varsha, Marina

• Granulocytic sarcoma: 32 cases and review of the literature

  Citation: 216

  Authors: Semra, Suzan, Melek

---